Venrock Adviser, LLC — 13F Holdings & Portfolio
CIK 1615982 · latest 13F-HR filed 2026-08-14
Venrock Adviser, LLC manages $3.30B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are APGE (34.18%), ORKA (11.97%), ERAS (9.94%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions and exited 4; 18 existing positions rose in reported value and 6 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 80.4%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- APOGEE THERAPEUTICS INC$412.4M +57.7%
- ORUKA THERAPEUTICS INC$191.3M +94.0%
- SPYRE THERAPEUTICS INC$79.2M +42.6%
- ERASCA INC$62.7M +23.7%
- JADE BIOSCIENCES INC$26.3M +58.1%
Top Trims
- ENLIVEN THERAPEUTICS INC-$41.0M -60.5%
- CYTOMX THERAPEUTICS INC-$28.2M -60.2%
- VIRIDIAN THERAPEUTICS INC-$16.1M -21.2%
- COGENT BIOSCIENCES INC-$13.4M -17.4%
- ORIC PHARMACEUTICALS INC-$7.9M -14.5%
New Positions
- ACHIEVE LIFE SCIENCE INC$18.0M
- PARABILIS MEDICINES INC$17.1M
- RESEARCH ALLIANCE CORP III$3.2M
- INMED PHARMACEUTICALS INC$50.7K
Exited Positions
- KALVISTA PHARMACEUTICALS INC$130.3M
- ENGENE HOLDINGS INC$32.5M
- TENAX THERAPEUTICS INC$26.8M
- SEPTERNA INC$12.2M
Venrock Adviser, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $1.13B | 34.18% | 8,493,321 | SH |
| 2 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $394.8M | 11.97% | 4,148,428 | SH |
| 3 | ERASCA INC | ERAS | 29479A108 | $327.8M | 9.94% | 17,891,812 | SH |
| 4 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $265.0M | 8.04% | 2,985,448 | SH |
| 5 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $115.0M | 3.49% | 1,180,000 | SH |
| 6 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $101.6M | 3.08% | 10,346,926 | SH |
| 7 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $93.7M | 2.84% | 3,603,595 | SH |
| 8 | SAVARA INC | SVRA | 805111101 | $90.8M | 2.75% | 14,745,943 | SH |
| 9 | JADE BIOSCIENCES INC | JBIO | 008064206 | $71.6M | 2.17% | 3,220,364 | SH |
| 10 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $63.6M | 1.93% | 1,642,166 | SH |
| 11 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $59.8M | 1.81% | 3,257,917 | SH |
| 12 | VOR BIOPHARMA INC | VOR | 929033207 | $56.0M | 1.70% | 3,041,719 | SH |
| 13 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $48.3M | 1.46% | 2,173,913 | SH |
| 14 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $47.8M | 1.45% | 1,602,034 | SH |
| 15 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $47.4M | 1.44% | 6,844,305 | SH |
| 16 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $46.8M | 1.42% | 4,319,765 | SH |
| 17 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $38.4M | 1.16% | 2,133,576 | SH |
| 18 | ZURA BIO LTD | ZURA | G9TY5A101 | $38.0M | 1.15% | 6,434,990 | SH |
| 19 | ADLAI NORTYE LTD | ANL | 00704R109 | $36.9M | 1.12% | 3,212,731 | SH |
| 20 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $26.7M | 0.81% | 526,331 | SH |
| 21 | CYBIN INC | HELP | 23256X407 | $25.5M | 0.77% | 3,851,654 | SH |
| 22 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $25.1M | 0.76% | 1,379,965 | SH |
| 23 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $21.3M | 0.65% | 8,695,652 | SH |
| 24 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $19.8M | 0.60% | 2,043,596 | SH |
| 25 | CYTOMX THERAPEUTICS INC | CTMX | 23284F105 | $18.7M | 0.57% | 4,982,124 | SH |
| 26 | ACHIEVE LIFE SCIENCE INC | QUIT | 004468500 | $18.0M | 0.54% | 2,751,032 | SH |
| 27 | PARABILIS MEDICINES INC | PBLS | 698955101 | $17.1M | 0.52% | 625,000 | SH |
| 28 | SURROZEN INC | SRZN | 86889P208 | $16.4M | 0.50% | 632,931 | SH |
| 29 | KORRO BIO INC | KRRO | 500946108 | $13.3M | 0.40% | 1,009,500 | SH |
| 30 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $13.2M | 0.40% | 500,000 | SH |
| 31 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $9.0M | 0.27% | 1,934,253 | SH |
| 32 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $3.2M | 0.10% | 300,000 | SH |
| 33 | INMED PHARMACEUTICALS INC | INM | 457637700 | $50.7K | 0.00% | 32,685 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $3.30B | 33 | 0001615982-26-000015 |
| 2026-03-31 | 2026-05-15 | $2.68B | 33 | 0001615982-26-000011 |
| 2025-12-31 | 2026-02-17 | $2.02B | 27 | 0001615982-26-000005 |
| 2025-09-30 | 2025-11-14 | $1.78B | 33 | 0001615982-25-000006 |
23RD FLOOR
NEW YORK, NY 10018